Hua Medicine Ltd. 2552

HKEX · Hong Kong SAR China · Health Technology

HKD 2.35+0.02 (+0.64%)

Market closed· Oct 2, 2026, 7:58 AM UTC· HKD · Data may be delayed

Company news

Yahoo FinanceMar 03, 2026

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.